Senseonics Holdings, Inc. · NASDAQ:SENS
Senseonics — Investor Presentation (November 2021)
20 slides from Senseonics's investor presentation, November 2021
Slide 1: Senseonics Eversense CGM System Corporate Presentation
Senseonics. Eversense CGM System The world’s FIRST and ONLY long-term Continuous Glucose Monitoring System Tim Goodnow, Corporate Presentation PhD November 2021 President and CEO
Slide 2: Forward-Looking Statements
FORWARD-LOOKING STATEMENTS This presentation, including the remarks of management contains forward-looking statements, as defined in the Private Securities Litigation Reform Act of 1995, statements regarding managements plans, objectives and goals for future operations, including preliminary targets
Slide 3: Our Mission
Slide 4: Corporate Overview and Milestones
CORPORATE OVERVIEW AND MILESTONES The FIRST and ONLY long-term and implantable CGM System. Available by prescription in US and select markets in Europe. Proven technology with rich development history, regulatory approvals and commercial accomplishments. 2016 2017 20 2019 2020 2021 ce ce FDA FDA FDA
Slide 5: High Growth Market
IGH GROWTH MARKET CGM Fastest Growing Diabetes Technology Segment Globally* CGM Global Market Size $8.2 $14B+ Annual:US Market Opportunity: $6.9 $2.7 “Estimates for top 4 CGM companies (Dexcom, Abbott, Medtronic 2017 2018 2019 2020 2021E 2022E and Senseonics), based upon available publicly stated gu
Slide 6: Significant Unmet Need Among BGM/CGM Users
SIGNIFICANT UNMET NEED AMONG BGM/CGM USERS xd Why BGM users won't adopt CGM! Most desired CGM improvements? * Longer Sensor Wear Device attached to body 45% > Better Accuracy Cost of CGM 40% Don't feel CGM is necessary 25% Dexcom i Medtronic Abbott Having to insert sensor into ; 20% i own skin Longe
Slide 7: Eversense CGM System addresses unmet needs
Eversense CGM System addresses unmet needs THE FIRS Taso ONLY = CGM that lasts for months vs days «= Implantable sensor = CGM to achieve 8.5% MARD - Transmitter that is removable «= System with on-body vibe alerts for hypo and hyper warnings «= System with fresh, gentle-on skin adhesive patch - Devi
Slide 8: Eversense US Patient Profiles
EF VERSENSE US PATIENT PROFILES' Broad appeal of Eversense with new and existing CGM users Target patient profiles = Dissatisfied with Current CGM = New to CGM with Reason = Gateway (Libre) Top preferred features of existing users = Accuracy = Sensor Life = Implantable Convenience 1 Senseonics Analy
Slide 9: Proven Efficacy in Real-World Use
PROVEN EFFICACY IN REAL-WORLD USE 1) High % of time wearing device and staying within range 1) Effectiveness improves with age Europe Multi-Sensor Users? Users by Age n=945 1656 Single | Sensor | Sensor | Sensor | Sensor % Time 70-180 mg/dL Sensor | Cycle1 | Cycle 2 | Cycle 3 | Cycle 4 % Time <70 mo
Slide 10: Positive & Growing Reimbursement
POSITIVE & GROWING REIMBURSEMENT Commercial and Medicare coverage for 200 million lives ) Medicare National Coverage = Therapeutic CGM Indication * Part B Medical Services = CMS National Payment Rate = Providers bill Medicare directly with existing CPT codes to include cost of device and procedure t
Slide 11: Commercial Collaboration with Ascensia
COMM ERCIAL COLLA BORATION WIT ASCENSIA = Broad Partnership Features Global Commercialization and Financing Arrangements with Leader in BGM * ASCENSIA is the Exclusive Worldwide Distribution Partner for Eversense®, Eversense® XL and Future Generation Products = Senseonics to Focus Streamlined Operat
Slide 12: Eversense Pipeline
EVERSENSE PIPELINE
Slide 13: Product Vision
PRODUCT VISION All Diabetes Patient Segments NO sensor change for 1 year NO daily calibration required NO transmitter on body NOTE: Product vision subject to a number of assumptions and regulatory approval. Corporate Presentation, updated November 2021
Slide 14: Senseonics Product Pipeline
SENSEONICS PRODUCT PIPELINE 2016 - 2020 2021 - 2025 Eversense® CGM 180D CGM BGM Connectivity 90-day CGM system 6-month sensor with Direct communication advanced chemistry with Ascensia Contour Eversense® XL CGM and features Meter 180-day CGM system New Mobile App Pump Integration Eversense® DMS Refr
Slide 15: New: Eversense 365
NEW: EV ERS ENS E 180 Extended duration of current sensor and with fewer calibrations ~ TECHNOLOGY Geni sensor with advanced chemistry, updated algorithm USE CASE Full year use with only 1 sensor change TARGET PMA Supplement Submitted Sept 30, 2020 © 2021 Senseonics™ Corporate Presentation, updated
Slide 16: Results from PROMISE Study
RESULTS FROM PROMISE STUDY' MARD: 8.5 = 9.1% 1) Exceptional Performance for Duration of 180 Days * Prospective multi-center pivotal trial at Accurate and stable for 6 months Highly accurate - 8 sites in the US for new 180-day sensor Percent of readings within 15 mg/dL or 15% of particularly in low r
Slide 17: Eversense System
EVERSENSE 365 SYSTEM One annual sensor for use as CGM for peace of mind and FGM for discretion TECHNOLOGY _ Gen 2 sensor (Rome); array-based sensing TARGET Intensively managed patients who want better control + All insulin-using patients NOTE: Timelines and development attributes subject to a number
Slide 18: Freedom System
FREEDOM SYSTEM Autonomous sensor testing with data processing capacity enabling 2 products from 1 platform TECHNOLOGY Enhanced Rome 2 sensor with integrated battery; updated algorithm USE CASE Full year use with 1 sensor and 1 cal/week Two unique products: 1. CGM with transmitter/FGM without transmi
Slide 19: Eversense Continuous Glucose Monitoring System
ae “e\/ersense. Continuous Glucose Monitoring System “ACCURATE. CONVENIENT. LIFE-CHANGIN e€Versense. Continuous Glucose Monitoring System 19
Slide 20: Thank You
THANK YOU
Senseonics Holdings — Investor Presentation (November 2021) on 6ix